Boston Scientific has lost more than half its value in eleven months, and almost every explanation you will read blames a slowdown. That is true but imprecise, and the imprecision is where the opportunity or the trap sits. The company’s June-quarter results were not weak: net sales rose 7.5% to $5.442bn, gross margin expanded 305 basis points to 70.7%, and operating income rose 43.8% to $1.178bn. What broke is narrower and more specific than “growth slowed” — and it is not visible in the headline franchise numbers. BSX closed at $51.83 on 14 August 2026, down 52.1% from its $108.14 peak close of 8 September 2025 and 45.3% year to date. It now trades at roughly 15.7 times the midpoint of its own full-year adjusted earnings guidance. The multiple, not the business, did the damage.
Here is the part almost nobody is quoting, and it comes out of the segment table in the 10-Q rather than the press release. Watchman revenue grew 4.3% and electrophysiology grew 9.0% — soft for franchises that carried this stock, but survivable. Split them by geography and the picture changes completely: US Watchman grew 2.9% and US electrophysiology grew 3.2%, while the same two franchises grew 20.0% and 23.0% internationally. The international strength is masking a near-stall in the market that sets the multiple. That is a materially different problem from a global deceleration, because it points at US competition and US account penetration rather than at demand for the therapy. Everything in the bull and bear case below turns on whether that US line reaccelerates.
Key facts
- Q2 2026 net sales: $5.442bn, up 7.5% reported and 7.0% organic — (Boston Scientific Form 10-Q, filed 3 August 2026)
- Gross margin: 70.7%, up 305 basis points from 67.7% a year earlier — (Form 10-Q)
- Operating income: $1.178bn, up 43.8%; operating margin 21.6% versus 16.2% — (Form 10-Q)
- US Watchman +2.9%, US electrophysiology +3.2% — against +20.0% and +23.0% internationally — (Form 10-Q franchise table)
- Full-year organic revenue guidance cut to 5–6% from 5–7%; Q3 organic guided to just 3–5% — (Q2 2026 results, 29 July 2026)
- Cash fell to $539m from $1.965bn at year-end, with current debt obligations up to $1.709bn from $299m — (Form 10-Q)
- $14.5bn Penumbra acquisition pending, announced 15 January 2026 at $374 per share, 73% cash — (Boston Scientific announcement, 15 January 2026)
- Spot: $51.83 at the 14 August 2026 close, 52.1% below the peak close — (daily closes, stockanalysis.com)
What actually happened to the share price
This was not a drift. It was two step-downs and a long grind between them, and the dates matter because each one repriced a different assumption.
On 4 February 2026 the stock fell 17.59% in a single session, closing at $75.50. That was the quarter where forward guidance came in below expectations and the market first questioned whether the double-digit organic growth algorithm was intact. On 27 May 2026 it fell a further 12.46% to $50.46, when management signalled that Watchman revenue would be roughly flat sequentially. Between and after those two days the shares ground to a trough close of $42.63 on 14 July before recovering to the current $51.83, which is 22.8% above that low.
The important thing about both drops is what they were not. Neither was a profit warning in the conventional sense, and neither followed a revenue miss. Q2 adjusted earnings per share of $0.86 came in above the company’s own $0.82–$0.84 guidance range and grew 15% year over year — though management noted the beat was helped by favourable tax results, which is worth discounting. Revenue beat. Margins expanded. What the market sold was the growth rate, and specifically the durability of the growth rate.
That distinction is the whole investment case. A company that misses on profitability has an execution problem. A company that beats on profitability while its two flagship US franchises decelerate to low single digits has a competitive problem, and competitive problems take longer to fix but do not usually impair the cash flows in the meantime.
Where the growth actually went
The franchise detail in the quarterly filing is unusually clear once you separate US from international.
| Franchise (Q2 2026) | US growth | International growth | Total |
|---|---|---|---|
| Interventional Cardiology & Vascular | +17.4% | +9.9% | +13.2% |
| Interventional Oncology & Embolization | +12.9% | +12.5% | +12.7% |
| Electrophysiology | +3.2% | +23.0% | +9.0% |
| Watchman | +2.9% | +20.0% | +4.3% |
| Cardiac Rhythm Management | −1.7% | +0.4% | −0.8% |
Two franchises are still compounding at low-to-mid teens in the United States. Cardiac rhythm management is in mild decline, which is a structural, long-understood feature of that market rather than news. The anomaly is electrophysiology and Watchman: both grew more than 20% internationally and both stalled domestically, in the same quarter, in the same segment.
The internal contrast is what makes this diagnosable. If the therapy itself were losing favour, international growth would not be running above 20%. If it were a pricing problem, margins would not have expanded 305 basis points. The most consistent reading of these numbers is that the US market for pulsed-field ablation and left-atrial-appendage closure has become genuinely competitive at exactly the point where Boston Scientific had the highest share and the least room to add new accounts — while international markets are still in the earlier, land-grab phase of the same adoption curve.
At the segment level, cardiovascular grew 8.3% and MedSurg 5.9%, giving the 7.5% total. Neither is a bad number in absolute terms. Both are far below what a stock priced in the mid-thirties on forward earnings, as BSX was a year ago, requires.
The mechanism behind the US stall is worth stating plainly, because it determines whether it is temporary. Pulsed-field ablation — the technology underneath the electrophysiology franchise — moved from novelty to standard of care in US cardiac centres extraordinarily fast, and Boston Scientific was the principal beneficiary of that shift. Being first into a rapidly adopted category produces spectacular growth rates for as long as there are untreated accounts to convert. It also means that when rival systems reach the market, the incumbent has the most share to defend and the fewest new hospitals left to sign. The same logic applies to Watchman, where Boston Scientific has been the dominant left-atrial-appendage closure device for years. International growth above 20% in both franchises is not a contradiction of this reading — it is confirmation of it, because those markets are two to three years behind the US on the same adoption curve.
If that reading is right, the US lines do not snap back to double digits. They stabilise somewhere in the mid single digits as a mature, defended, high-margin business, and the international ramp carries group growth for the next several years. That is a perfectly good company. It is simply not the company the September 2025 share price was describing.
The valuation reset, and the deal underneath it
Full-year guidance now calls for 5–6% organic revenue growth and adjusted EPS of $3.28–$3.32, up 7–8%. Third-quarter organic growth is guided at 3–5%. At $51.83, the shares trade on about 15.7 times the $3.30 guidance midpoint. Analyst consensus, which fell 13% after the second-quarter report, now sits at $62.69 — and the rating distribution has not broken: of 29 analysts, 26 rate the stock a buy, five a hold, and none a sell. That combination, sharply reduced targets with an intact buy rating, is the signature of a de-rating rather than a thesis collapse.
The half-year figures reinforce the point that this is a de-rating rather than a deterioration, with one caveat worth flagging. Across the first six months of 2026, net sales rose 9.5% to $10.646bn, operating income rose 31.0% to $2.279bn, and net income attributable to common stockholders rose 52.8% to $2.247bn, taking diluted EPS to $1.51 from $0.98. That last figure is flattered and should not be annualised: the company recorded a discrete tax benefit in the first quarter, which turned the six-month income tax line into a net benefit of $21m against a $279m expense a year earlier. Strip the tax effect and the underlying improvement is still real but far less dramatic — which is exactly why the adjusted EPS guidance of $3.28–$3.32, rather than the reported first-half number, is the right basis for a multiple.
One further detail cuts against the idea of a company in trouble: the diluted share count fell to 1,474.8m from 1,493.5m a year earlier, a reduction of about 1.3%. Boston Scientific has been retiring stock rather than issuing it, even while assembling cash for a very large acquisition. Inventories rose 9.9% to $3.235bn, broadly in line with sales growth rather than running ahead of it, which argues against a channel-stuffing or destocking problem sitting behind the US deceleration.
What almost no coverage connects is the timing of the balance sheet. On 15 January 2026 — three weeks before the first 17.6% drop — Boston Scientific agreed to acquire Penumbra for approximately $14.5bn, at $374 per Penumbra share, structured roughly 73% cash and 27% stock, with closing expected in the second half of 2026. It is the company’s largest acquisition in around two decades and takes it deep into mechanical thrombectomy and neurovascular devices.
The consequences are already visible in the filing. Cash and equivalents fell from $1.965bn at 31 December to $539m at 30 June, other investments rose from $681m to $2.245bn, and current debt obligations jumped from $299m to $1.709bn. Boston Scientific is pre-positioning to fund a very large cash acquisition at the same moment its two highest-multiple franchises decelerated in their home market. That is the actual risk, and it is a sequencing risk rather than a solvency one: leverage stood at 2.02 times against a 4.00 times covenant limit, so the balance sheet has real room.
For readers tracking how the market is repricing growth names on multiple rather than earnings this month, our HIMS bull and bear analysis covers the same mechanic in a healthcare context, and today’s Applied Optoelectronics analysis shows the mirror image — a stock where the multiple expanded while margins fell.
What has to be true for each case
The bull case to $72 (+38.9%). This does not require a return to double-digit organic growth. It requires two things: that US electrophysiology and Watchman stop decelerating — stabilising in the mid single digits is enough — and that Penumbra closes on schedule and is integrated without a guidance reset. On the $3.30 adjusted EPS midpoint, $72 is about 21.8 times earnings, which is a normal multiple for a large-cap medical device company with 70% gross margins and a 21.6% operating margin. This is a re-rating case, not a growth-reacceleration case, and that is precisely what makes it plausible. It sits above the $62.69 consensus, so treat it as the upper scenario rather than the base.
The bear case to $40 (−22.8%). This requires the US stall to persist into 2027 and spread. If electrophysiology and Watchman go from low-single-digit growth to flat or negative in the US while international decelerates off its own high base, full-year organic growth drops toward 3–4% and adjusted EPS growth toward the low single digits. A company growing earnings 3% does not hold a 15.7 times multiple; 12 times on $3.30 is $39.6. That path breaks the 52-week low of $42.20 and would likely be accompanied by Penumbra integration costs arriving before Penumbra revenue synergies. Note that no analyst currently carries a sell rating, which means this scenario is not priced by the sell side at all.
The tell to watch is not the revenue line. It is the US electrophysiology and Watchman growth rates in the third-quarter filing, which the company breaks out by geography. Two consecutive quarters of US growth below 3% would confirm the bear path; a print back above 6% would make the current multiple look like the mistake.
Frequently asked questions
Why has Boston Scientific stock fallen so much in 2026?
Not because of losses — the company is more profitable than a year ago. The decline came from two guidance-driven sessions: a 17.6% drop on 4 February 2026 after soft forward guidance, and a 12.5% drop on 27 May 2026 after management signalled flat sequential Watchman revenue. The market re-rated the growth multiple rather than the earnings.
Is Boston Scientific still profitable?
Yes, and increasingly so. Second-quarter operating income rose 43.8% to $1.178bn, gross margin expanded 305 basis points to 70.7%, and GAAP diluted EPS rose to $0.61 from $0.53. Adjusted EPS of $0.86 beat the company’s own guidance range.
What is the Watchman problem?
Watchman is Boston Scientific’s left-atrial-appendage closure device. US revenue grew only 2.9% year over year in Q2 2026, against 20.0% growth internationally. Management indicated revenue would be roughly flat sequentially, which triggered the May sell-off. The issue appears to be US competition and account saturation rather than falling demand for the therapy.
What is Boston Scientific buying Penumbra for?
Penumbra is a mechanical thrombectomy and neurovascular device maker. The deal was announced on 15 January 2026 at roughly $14.5bn, or $374 per Penumbra share, paid approximately 73% in cash and 27% in stock, with closing expected in the second half of 2026. It returns Boston Scientific to the neurovascular market it exited in 2011.
Is BSX cheap at these levels?
On the numbers, it trades at about 15.7 times the midpoint of full-year adjusted EPS guidance of $3.28–$3.32, against a consensus price target of $62.69. Whether that is cheap depends entirely on whether 5–6% organic growth is the new normal or a trough. A 15.7 multiple is undemanding for a business with 70% gross margins and demanding for one growing 3%.
What would change the thesis fastest?
The geographic split of electrophysiology and Watchman growth in the third-quarter report. Those two lines, US only, are the variables the entire re-rating hangs on.
Related reading on FinanceFeeds: our Nokia bull and bear case and the Reddit RDDT price prediction apply the same scenario framework to different sectors, while the Nebius post-Q2 analysis covers a name repricing in the opposite direction.
Sources: Boston Scientific Form 10-Q for the quarter ended 30 June 2026, filed with the SEC on 3 August 2026; Q2 2026 results announced 29 July 2026; the Penumbra acquisition announcement of 15 January 2026; price data from stockanalysis.com as at the 14 August 2026 close.
This article is analysis, not investment advice. The bull and bear figures are scenarios constructed from published filings and company guidance, not price targets or recommendations. Readers should conduct their own research before making investment decisions.